



## Second Quarter 2017 Recommendations

Highlighted below are additional recommendations based on communication with the Georgia Medicaid Fee-for-Service Drug Utilization Review (DUR) Board prior to the May DUR Board meeting. The current preferred drug list (PDL) status for all drugs can be found at <http://dch.georgia.gov/preferred-drug-lists>.

### Aminoglycosides for Cystic Fibrosis

The DUR Board recommended *Preferred* status for *Bethkis (Inhalation) Solution*.

### Anaphylaxis, Epinephrine Pens

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *EpiPen (Intramuscular/Subcutaneous) Injection* and *Preferred* status for *select generics of Epinephrine (Intramuscular/Subcutaneous) Injection*.

### Antidementia Agents

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Namenda (Oral) Titration Pak* and *Preferred* status for *generic Memantine (Oral) Titration Pak*.

### Antidiabetics, Non-Insulin, DPP-4 Inhibitors

The DUR Board recommended *Preferred* status for *Januvia (Oral) Tablet, Janumet (Oral) Tablet, Jentadueto (Oral) Tablet, Kombiglyze (Oral) Tablet, Onglyza (Oral) Tablet, and Tradjenta (Oral) Tablet*.

### Antiemetics

The DUR Board recommended *Preferred* status for *Diclegis (Oral) Tablet*.

### Antihyperlipidemics

The DUR Board recommended *Preferred* status for *Zetia (Oral) Tablet*.

### Antivirals, Hepatitis Agents

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Sovaldi (Oral) Tablet*.

### Attention Deficit Hyperactivity Disorder (ADHD) Agents

The DUR Board recommended deferral of decisions in this category until a comprehensive review of class, including revised financial offers, is conducted. Following the meeting, the DUR Board recommended, via an electronic vote, *Non-Preferred* status with *Prior Authorization* for *methylphenidate ER (Oral) tablet* and *Non-Preferred* status with *Prior Authorization* for *methylphenidate LA (Oral) capsule*.

### Gastrointestinal, Inflammatory Bowel Agents

The DUR Board recommended *Preferred* status for *Lialda (Oral) Tablet*.